Gene therapy/bone marrow transplantation in ADA-deficient mice: Roles of enzyme-replacement therapy and cytoreduction

Blood

Volumn 120, Issue 18, 2012, Pages 3677-3687

  Carbonaro Sarracino, Denise Ann ^a   Jin, Xiangyang ^a   Wang, Xingchao ^b   Yu, Xiao Jin ^b   Rozengurt, Nora ^a   Kaufman, Michael L ^a   Wang, Xiaoyan ^c   Gjertson, David ^c   Zhou, Yang ^d   Blackburn, Michael R ^d   Kohn, Donald B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; COPY NUMBER VARIATION; CYTOREDUCTIVE SURGERY; ENZYME ACTIVITY; ENZYME REPLACEMENT; GENE THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECIPIENT; THYMOCYTE; TREATMENT DURATION; WHOLE BODY RADIATION;

EID: 84868600881     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-408591     Document Type: Article

References (45)

1. Hershfield MS. Genotype is an important determinant of phenotype in adenosine deaminase deficiency. Curr Opin Immunol. 2003;15(5):571-577. (Pubitemid 37130199)
2. Morgan G, Levinsky RJ, Hugh-Jones K, et al. Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase. Clin Exp Immunol. 1987;70(3):491-499. (Pubitemid 18013186)
3. Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notaranglelo LD. How I treat ADA deficiency. Blood. 2009;114(17):3524-3532.
4. Chan B, Wara D, Bastian J, et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol. 2005;117(2):133-143. (Pubitemid 41407723)
5. Malacarne F, Benicchi T, Notarangelo LD, et al. Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients. Eur J Immunol. 2005;35(11):3376- 3386. (Pubitemid 41672541)
6. Anderson WF. Prospects for human gene therapy. Science. 1984;226(4673):401-109.
7. Hirschhorn R. In vivo reversion to normal of inherited mutations in humans. J Med Genet. 2003;40(10):721-728. (Pubitemid 37311069)
8. Ariga T, Oda N, Yamaguchi K, et al. T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation. Blood. 2001;97(9):2896-2899.
9. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 1995;270(5235):475-480.
10. Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA immunodeficient patients. Science. 1995;270(5235):470-475.
11. Hoogerbrugge PM, van Beusechem VW, Fisher A, et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 1996;3(2):179-183. (Pubitemid 26117428)
12. Kohn DB, Weinberg KI, Nolta JA, et al. Engraftment of gene-modified cells from umbilical cord blood in neonates with adenosine deaminase deficiency. Nat Med. 1995;1(10):1017-1026.
13. Kohn DB, Hershfield MS, Carbonaro D, et al. T lymphocytes with a normal Ada gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADAdeficient SCID neonates. Nat Med. 1998;4(7):775-780. (Pubitemid 28331017)
14. Aiuti A, Vai S, Mortellaro A, et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med. 2002;8(5):423-425. (Pubitemid 34546725)
15. Schmidt M, Carbonaro D, Speckmann C, et al. Clonality analysis after retroviral-mediated gene transfer to cord blood CD34+ cells of an ADA-deficient SCID infant. Nat Med. 2003;9(4):463-468. (Pubitemid 36460082)
16. Muul LM, Tuschong LM, Soenen SL, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood. 2003;101(7):2563-2569. (Pubitemid 36857614)
17. Sokolic R, Podsakoff G, Muul L, et al. Comparative results of gene therapy for adenosine deaminase deficiency with or without PEG-ADA withdrawal and myelosuppressive chemotherapy. Blood. 2011;118(10):2688-2694.
18. Aiuti A, Slavin S, Aker M, et al. Correction of ADASCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296(5577):2410-2413. (Pubitemid 34734219)
19. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447-458.
20. Gaspar HB, Bjorkegren E, Parsley K, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther. 2006;14(4):505-513. (Pubitemid 44339393)
21. Shaw KL, Choi Y, Muul L, et al. Update on a clinical gene therapy trial for adenosine deaminase deficient severe combined immune deficiency (ADA-SCID). Mol Ther. 2010;18(12):S296.
22. Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med. 2011;3(97):97ra80.
23. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989;7(9):980-990. (Pubitemid 19262578)
24. Challita PM, Skelton D, El-Khoueiry A, et al. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol. 1995;6(2):748-755.
25. Haas DL, Lutzko C, Logan A, et al. The Moloney murine leukemia virus repressor binding site represses expression in murine and human hematopoietic stem cells. J Virol. 2003;77(17):9439-9450. (Pubitemid 37011040)
26. Krall WJ, Skelton DC, Yu X-J, et al. Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells. Gene Ther. 1996;3(1):37-48. (Pubitemid 26084937)
27. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on 2 different plasmids. J Virol. 1988;62(4):1120-1124. (Pubitemid 18082924)
28. Blackburn MR, Datta SK, Kellems RE. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem. 1998;273(9):5093-5100. (Pubitemid 28108669)
29. Blackburn MR, Aldrich M, Volmer JB, et al. The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. J Biol Chem. 2000;275(41):32114-32121.
30. Carbonaro DA, Jin X, Cotoi D, et al. Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion. Blood. 2008;111(12):5745-5754.
31. Hendrickson B, Senadheera D, Mishra S, et al. Development of lentiviral vectors with regulated respiratory epithelial expression in vivo. Am J Respir Cell Mol Biol. 2007;37(4):414-423. (Pubitemid 47502716)
32. Carbonaro DA, Jin X, Petersen D, et al. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knock-out mice: a novel form of enzyme replacement therapy for ADA-deficiency. Mol Ther. 2006;13(6):1110-1120. (Pubitemid 43779186)
33. Wang L-J, Chen YM, George D, et al. Engraftment assessment in human and mouse liver tissue after sex-mismatched liver cell transplantation by real-time quantitative PCR for Y chromosome sequences. Liver Transpl. 2002;8(9):822-828. (Pubitemid 35012294)
34. Knudsen TB, Winters RS, Otey, SK, et al. Effects of R-deoxycoformycin (pentostatin) on intrauterine nucleoside catabolism and embryo viability in the pregnant mouse. Teratology. 1992(1):45:91-103.
35. Tukey JW. Variances of variance components: II. Unbalanced single classifications. Ann Mathematical Stat. 1957;28(1):43-56.
36. Kruskal W, Wallis WA. Use of ranks in onecriterion variance analysis. J Am Stat Assoc. 1952;47(1):583-621.
37. SAS Institute. SAS/STAT 9.2 User's Guide. Cary, NC: SAS Institute; 2008.
38. Otsu M, Yamada M, Maeyama Y, et al. Update of Stem Cell Gene Therapy Clinical Trial for ADA-deficiency in Japan. Mol Ther. 2010;18(12):S678.
39. Sadat MA, Discherl S, Sastry L, et al. Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation. Gene Ther. 2009;16(12):1452-1464.
40. Min D, Taylor PA, Panoskaltsis-Morari A, et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood. 2002;99(12):4592-4600. (Pubitemid 34627232)
41. Arredondo-Vega FX, Santisteban I, Richard E, et al. Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy. Blood. 2002;99(3):1005-1013. (Pubitemid 34525565)
42. Kohn DB. Adenosine deaminase gene therapy protocol revisited. Mol Ther. 2002;5(2):96-97. (Pubitemid 34144824)
43. Thompson LF, Van de Wiele CJ, Laurent AB, et al. Metabolites from apoptotic thymocytes inhibit thymopoiesis in adenosine deaminasedeficient fetal thymic organ cultures. J Clin Invest. 2000;106(9):1149-1157.
44. Sauer AV, Mrak E, Hernandez RJ, et al. ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANK/OPG imbalance and osteoblast insufficiency. Blood. 2009;114(15):3216-3226.
45. Booth C, Algar VE, Xu-Bayford J, et al. Non-infectious lung disease in patients with adenosine deaminase deficient severe combined immunodeficiency. J Clin Immunol. 2012;32(3):449-453.